INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
27 juin 2024 08h00 HE
|
INmune Bio, Inc.
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party,...
Frontier Science Scotland Strengthens Board of Trustees with New Appointment
17 juin 2024 04h00 HE
|
Frontier Science Scotland
KINCRAIG, Scotland, June 17, 2024 (GLOBE NEWSWIRE) -- Frontier Science Scotland (FSS), a leading contract clinical research organisation, advancing drug development by delivering excellence in...
CenExel Highlights High Level of Psychometric Rater Stress and Burnout
29 mai 2024 13h00 HE
|
CenExel Clinical Research
Salt Lake City, Utah, May 29, 2024 (GLOBE NEWSWIRE) -- Poster presented today at American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida, shows: High levels of...
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
30 oct. 2023 09h07 HE
|
INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
06 oct. 2023 07h50 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
03 oct. 2023 07h50 HE
|
Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
29 sept. 2023 07h45 HE
|
SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
Folia Health launches user-led research program, the Canopy Series
23 mai 2023 10h09 HE
|
Folia Health
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Today, Folia Health announced a first-of-its-kind observational research initiative driven by the priorities of patient and caregiver users. This program,...
Sensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
17 mai 2023 08h00 HE
|
Sensus Healthcare, Inc.
BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment,...
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
02 mai 2023 07h25 HE
|
SciSparc Ltd
The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...